Your browser doesn't support javascript.
loading
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.
Stockbridge, Norman; Miller, Kristen; Amur, Shashi; Hillebrenner, Matthew; Zuckerman, Bram; Fiuzat, Mona; Califf, Robert M.
Affiliation
  • Stockbridge N; U.S. Food and Drug Administration, Silver Spring, Maryland. Electronic address: Norman.stockbridge@fda.hhs.gov.
  • Miller K; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Amur S; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Hillebrenner M; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Zuckerman B; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Fiuzat M; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Califf RM; U.S. Food and Drug Administration, Silver Spring, Maryland.
JACC Heart Fail ; 5(1): 67-70, 2017 01.
Article in En | MEDLINE | ID: mdl-28034379
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality Control / United States Food and Drug Administration / Cardiovascular Agents / Drug Approval / Heart Failure Limits: Humans Country/Region as subject: America do norte Language: En Journal: JACC Heart Fail Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality Control / United States Food and Drug Administration / Cardiovascular Agents / Drug Approval / Heart Failure Limits: Humans Country/Region as subject: America do norte Language: En Journal: JACC Heart Fail Year: 2017 Document type: Article